Leerink Partnrs Brokers Lower Earnings Estimates for Bruker

Bruker Co. (NASDAQ:BRKR) – Equities research analysts at Leerink Partnrs cut their Q4 2024 earnings per share estimates for shares of Bruker in a report released on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $0.73 per share for the quarter, down from their prior estimate of $0.95. The consensus estimate for Bruker’s current full-year earnings is $2.39 per share. Leerink Partnrs also issued estimates for Bruker’s Q1 2025 earnings at $0.54 EPS, Q2 2025 earnings at $0.59 EPS, Q4 2025 earnings at $0.90 EPS, FY2025 earnings at $2.73 EPS, Q1 2026 earnings at $0.70 EPS, Q2 2026 earnings at $0.74 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $3.22 EPS.

A number of other equities analysts also recently weighed in on the stock. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Citigroup lowered their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday. TD Cowen reduced their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday. Wells Fargo & Company dropped their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Barclays cut their target price on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.36.

Bruker Stock Down 4.6 %

Bruker stock opened at $57.73 on Friday. The stock has a market cap of $8.74 billion, a PE ratio of 27.75, a price-to-earnings-growth ratio of 2.83 and a beta of 1.20. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.75 and a current ratio of 1.66. The firm’s 50-day simple moving average is $63.64 and its 200 day simple moving average is $66.21. Bruker has a fifty-two week low of $54.55 and a fifty-two week high of $94.86.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. During the same period in the previous year, the company earned $0.74 earnings per share. Bruker’s revenue for the quarter was up 16.4% compared to the same quarter last year.

Institutional Investors Weigh In On Bruker

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank increased its position in shares of Bruker by 11.3% in the third quarter. Swiss National Bank now owns 206,900 shares of the medical research company’s stock valued at $14,289,000 after acquiring an additional 21,000 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of Bruker by 2.8% during the third quarter. Thrivent Financial for Lutherans now owns 90,284 shares of the medical research company’s stock worth $6,235,000 after purchasing an additional 2,436 shares during the period. Mutual of America Capital Management LLC grew its stake in shares of Bruker by 7.1% in the third quarter. Mutual of America Capital Management LLC now owns 59,728 shares of the medical research company’s stock worth $4,125,000 after purchasing an additional 3,978 shares during the last quarter. Natixis Advisors LLC increased its holdings in Bruker by 12.3% during the 3rd quarter. Natixis Advisors LLC now owns 146,694 shares of the medical research company’s stock valued at $10,131,000 after purchasing an additional 16,044 shares during the period. Finally, Ferguson Wellman Capital Management Inc. raised its position in Bruker by 16.5% during the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 16,041 shares of the medical research company’s stock valued at $1,108,000 after purchasing an additional 2,270 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.